FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma

Okabe,Naoyuki; Ezaki,Junji; Yamaura,Takumi; Muto,Satoshi; Osugi,Jun; Tamura,Hirosumi; Imai,Jun‑Ichi; Ito,Emi; Yanagisawa,Yuka; Honma,Reiko; Gotoh,Mitsukazu; Watanabe,Shinya; Waguri,Satoshi; Suzuki,Hiroyuki

doi:10.3892/ijo.2015.2817

FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma

Authors:
- Naoyuki Okabe
- Junji Ezaki
- Takumi Yamaura
- Satoshi Muto
- Jun Osugi
- Hirosumi Tamura
- Jun‑Ichi Imai
- Emi Ito
- Yuka Yanagisawa
- Reiko Honma
- Mitsukazu Gotoh
- Shinya Watanabe
- Satoshi Waguri
- Hiroyuki Suzuki
View Affiliations

Affiliations: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima 960‑1295, Japan, Medical‑Industrial Translational Research Center, Fukushima Medical University, School of Medicine, Fukushima 960‑1295, Japan, Nippon Gene Co., Ltd., Chiyoda, Tokyo 101‑0054, Japan
Published online on: January 7, 2015 https://doi.org/10.3892/ijo.2015.2817
Pages: 999-1006
Copyright: © Okabe et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Personalized therapy for non‑small cell lung cancer (NSCLC), particularly lung adenocarcinoma, has recently been significantly improved by the discovery of various molecular targets. However, this has not been the case for lung squamous cell carcinoma (SCC). In the present study, we identified the family with sequence similarity 83, member B (FAM83B) as a candidate marker for SCC through a comprehensive gene expression analysis and examined its correlations with various clinicopathological factors. The subjects of this study consisted of 215 patients with NSCLC who underwent complete resection from 2005 to 2011 at the Fukushima Medical University Hospital (Fukushima, Japan). They included 102 patients with adenocarcinoma and 113 with SCC. FAM83B expression was first examined in some of the samples by gene expression analysis and western blotting, and then all clinical specimens were evaluated by immunohistochemistry (IHC). The relationship between the quantitative values for IHC and clinicopathological factors was statistically analyzed. The results showed that FAM83B mRNA expression was significantly higher in SCC than in normal lung or adenocarcinoma (P<0.0001). Immunoblot analysis also confirmed this trend. Specimens containing >10% positive area for FAM83B were judged as ‘positive’; 94.3% (107/113) of SCC and 14.7% (15/102) of adenocarcinoma were positive. Patients were divided into two subgroups according to expression (54 high‑expression and 53 low‑expression patients); the high‑expression group was associated with a better disease‑free survival (DFS) rate (P=0.042, log‑rank test). In conclusion, FAM83B may be a reliable diagnostic and prognostic biomarker for SCC. Detailed analyses of FAM83B function in lung cancer are required to understand how its expression is associated with better prognosis in SCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Travis WD: Pathology of lung cancer. Clin Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
3	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
4	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hainsworth JD, Fang L, Huang JE, et al: BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol. 6:109–114. 2011. View Article : Google Scholar
9	Turner NC and Seckl MJ: A therapeutic target for smoking-associated lung cancer. Sci Transl Med. 2:62ps562010. View Article : Google Scholar : PubMed/NCBI
10	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
11	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
12	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
13	Khuder SA: Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 31:139–148. 2001. View Article : Google Scholar : PubMed/NCBI
14	Rekhtman N, Paik PK, Arcila ME, et al: Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 18:1167–1176. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kim HS, Mitsudomi T, Soo RA and Cho BC: Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer. 80:249–255. 2013. View Article : Google Scholar : PubMed/NCBI
16	Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
17	Gold KA, Wistuba II and Kim ES: New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res. 18:3002–3007. 2012. View Article : Google Scholar : PubMed/NCBI
18	Cipriano R, Graham J, Miskimen KL, et al: FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest. 122:3197–3210. 2012. View Article : Google Scholar : PubMed/NCBI
19	Miura A, Honma R, Togashi T, et al: Differential responses of normal human coronary artery endothelial cells against multiple cytokines comparatively assessed by gene expression profiles. FEBS Lett. 580:6871–6879. 2006. View Article : Google Scholar : PubMed/NCBI
20	Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
21	Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
22	Ou SH and Zell JA: Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 4:1202–1211. 2009. View Article : Google Scholar : PubMed/NCBI
23	Noh S and Shim H: Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: a tissue microarray study of poorly differentiated areas. Lung Cancer. 76:51–55. 2012. View Article : Google Scholar
24	Ocque R, Tochigi N, Ohori NP and Dacic S: Usefulness of immu-nohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol. 136:81–87. 2011. View Article : Google Scholar : PubMed/NCBI
25	Conde E, Angulo B, Redondo P, et al: The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One. 5:e122092010. View Article : Google Scholar : PubMed/NCBI
26	Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD and Rekhtman N: p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 25:405–415. 2012. View Article : Google Scholar
27	Pelosi G, Fabbri A, Bianchi F, et al: ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 7:281–290. 2012. View Article : Google Scholar
28	Kogure Y, Ando M, Saka H, et al: Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol. 8:753–758. 2013. View Article : Google Scholar : PubMed/NCBI
29	Cipriano R, Bryson BL, Miskimen KL, et al: Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B. Oncogene. 33:3298–3306. 2014. View Article : Google Scholar :
30	Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA and Jackson MW: FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget. 4:729–738. 2013.PubMed/NCBI
31	Bass AJ, Watanabe H, Mermel CH, et al: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009. View Article : Google Scholar : PubMed/NCBI
32	Hussenet T, Dali S, Exinger J, et al: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 5:e89602010. View Article : Google Scholar : PubMed/NCBI
33	Wilbertz T, Wagner P, Petersen K, et al: SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 24:944–953. 2011. View Article : Google Scholar : PubMed/NCBI
34	Hilger M and Mann M: Triple SILAC to determine stimulus specific interactions in the Wnt pathway. J Proteome Res. 11:982–994. 2012. View Article : Google Scholar :